AOD-9604 does not affect IGF-1 levels, insulin sensitivity, or glucose tolerance
Choosing between them, or using them in tandem, depends on whether your primary goal is cost-effective glucose management or more aggressive metabolic and cardiovascular intervention.
Heres what to expect based on the general recommended starting dosage and administration of the brand-name medications that are FDA-approved for weight loss: Begin with Wegovy at a starting dose of 0.25 mg for the initial 4 weeks, then escalate to 0.5 mg from week 5 for another 4 weeks
typically this is a minimum of 5% of starting weight where appropriate
One syndrome that can go hand-in-hand with mast cell activation syndrome is Ehlers-Danlos, a tissue connectivity disorder
PubMed laboratory research record [PMID: 18416133] PubMed record related to this compound for laboratory literature review